Member of the Board since 2015.
Ingemar holds a PhD in Physiology and Associate Professor in Toxicology from Uppsala University. He has a broad experience in business development and drug development from e.g. Astra Zeneca and Pharmacia and the financial industry. He is the co-founder of several life-science companies and sits on many boards, mainly within Pharma, MedTech and Biotech.
Holdings in the company: 78,000 shares
Independence: Ingemar is independent in relation to the company and is independent in relation to the Company’s largest shareholders.